#China #Suzhou #CDMO Services #Porton Advanced #Drug Manufacturing

Porton Advanced Solutions Achieves a Significant Milestone

Porton Advanced Solutions Ltd., a leading player in the contract development and manufacturing organization (CDMO) space, has recently made headlines after being granted a Class C Drug Manufacturing License by China’s National Medical Products Administration (NMPA). This pivotal achievement is set to expand their capabilities in commercial contract manufacturing, particularly targeting the burgeoning fields of cell and gene therapies (CGT).

Significance of the Class C License

The Class C license is not just a regulatory formality but a significant aspect of Porton Advanced's operational framework. Under the Chinese drug manufacturing regulations, this license empowers the company to undertake contract manufacturing on behalf of a Marketing Authorization Holder (MAH). This legal certification is considered essential for any entity operating under the CDMO model, and it evidences Porton’s commitment to maintaining high compliance standards within the pharmaceutical manufacturing industry.

Following a successful regulatory inspection of its Good Manufacturing Practice (GMP) compliant commercial production facilities, Porton Advanced has received formal authorization to embark on commercial-scale manufacturing projects. This license enables them to bridge the gap between early-stage developmental processes and full-scale commercialization, a crucial path for biotechnology companies looking to scale their innovations for the market.

A Proven Track Record

Porton Advanced has established a reputation for delivering reliable, high-quality CDMO services to over 200 clients across the globe. Their quality assurance systems are designed to align with the rigorous standards imposed by regulatory bodies such as the NMPA, FDA, and EMA. Impressively, the company boasts a 100% success rate for Investigational New Drug (IND) submissions, underscoring their efficacy and reliability. To date, they have facilitated 26 global IND approvals across various jurisdictions, including notable achievements such as supporting the first in vivo CAR-T therapy to obtain IND approval in China.

The company’s breadth of experience also extends to managing 12 programs currently in Phase I/II trials or commercial-stage process modifications. Such accomplishments showcase Porton Advanced’s capability to support innovative therapies as they transition from the lab to real-world applications.

Comprehensive CDMO Services

The services offered by Porton Advanced encompass a variety of CGT products, which include plasmids, lentivirus, cell therapies (including in vivo CAR-T), mRNA-based therapies, and exosomes. They are currently working on an advanced cell therapy project that is on the cusp of a Biologics License Application (BLA) submission. The recent acquisition of the Class C Drug Manufacturing License positions Porton Advanced strategically to enhance their role as a trusted CDMO partner, especially in the realm of commercial manufacturing.

About Porton Advanced Solutions

Porton Advanced Solutions is a subsidiary of Porton Pharma Solutions, recognized as a leader in the CDMO landscape. The company operates dual headquarters in Cranbury, New Jersey, and Suzhou, China, delivering comprehensive end-to-end CDMO solutions for Advanced Therapy Medicinal Products (ATMPs). Their services encompass a spectrum of stages in drug development, ranging from cell banking and process development to clinical trials and eventual commercialization. Their facilities, spanning an impressive 215,000 square feet, feature 10 viral vector production lines and 12 cell therapy production suites, all adhering to stringent GMP standards, thus ensuring a robust capacity for the future demands of the biotech industry.

This significant licensing achievement is expected to enhance the infrastructure and operational capabilities of Porton Advanced and strengthen their position within the rapidly growing market for innovative therapies.